We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
- Authors
Lam, Stephen S. Y.; Ho, Eric S. K.; Bai-Liang He; Wui-Wing Wong; Chae-Yin Cher; Ng, Nelson K. L.; Cheuk-Him Man; Gill, Harinder; Cheung, Alice M. S.; Ho-Wan Ip; Chi-Chiu So; Jerome Tamburini; Chi Wai Eric So; Ho, Dona N.; Chun-Hang Au; Tsun-Leung Chan; Ma, Edmond S. K.; Liang, Raymond; Yok-Lam Kwong; Leung, Anskar Y. H.
- Abstract
The article presents a study which developed and validated a personalized treatment for relapsed/refractory acute myeloid leukemia (AML). Topics discussed include the preferential antileukemia effect of homoharringtonine (HHT) or omacetaxine mepesuccinate against AML-carrying internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-ITD) and the results of the phase 2 clinical trial of sorafenib and HHT combination treatment in FLT3-ITD AML patients.
- Subjects
ACUTE myeloid leukemia treatment; PROTEIN-tyrosine kinases; SORAFENIB; CLINICAL trials; KINASE inhibitors
- Publication
Science Translational Medicine, 2016, Vol 8, Issue 359, p1
- ISSN
1946-6234
- Publication type
Article
- DOI
10.1126/scitranslmed.aaf3735